1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Regenicin, Inc.

Regenicin, Inc.

RGIN
Regenicin, Inc.US flagOther OTC
0.00
USD
- -
- -
15,348.00Market Cap
Regenicin, Inc.
RGIN
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
-0.01
-0.06
-0.04
-0.05
0.02
- -
-0.01
-0.01
- -
-0.01
- -
- -
- -
-0.01
Basic EPS, GAAP
- -
- -
- -
-0.04
-0.02
-0.01
-0.01
- -
-0.01
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
-0.01
-0.06
-0.09
-0.12
-0.08
-0.07
-0.08
-0.08
-0.09
-0.09
-0.09
-0.1
-0.1
-0.11
Book Value per Share
- -
- -
- -
-0.01
-0.02
-0.04
-0.04
-0.01
- -
-0.01
-0.02
-0.02
-0.02
-0.03
-0.03
-0.04
-0.04
Tangible Book Value per Share
73
73
73
75
85
89
109
133
153
153
153
153
153
153
153
153
153
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
-1
-4
-3
-5
2
- -
-1
-1
-1
-1
-1
-1
-1
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
92.1
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-1
-1
-3
-4
-2
- -
-2
-2
-3
-4
-4
-5
-6
-6
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
2
2
- -
-4
-2
- -
-1
-2
-3
-4
-4
-5
-6
-6
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
-2.47
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'22
Dec'23
Mar'23
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
153
153
153
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'22
Dec'23
Mar'23
Total Current Assets
- -
12
12
Cash, Cash Equivalents & STI
- -
12
12
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
6
18
18
Payables & Accruals
5
5
5
ST Debt
1
1
1
Deferred Revenue
- -
12
13

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
106.31%
18.13%
12.89%
Free Cash Flow
61%
-2.47%
13.21%
Net Income, GAAP
-75.43%
-3.6%
-4.67%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
-24.79%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Hansa Biopharma AB (publ) (HNSA.ST)
Seaport Therapeutics, Inc. Common Stock (SPTX)
OncoCyte Corporation (OCX)
Hemagen Diagnostics, Inc. (HMGN)
Kymera Therapeutics, Inc. (KYMR)
Propanc Biopharma, Inc. (PPCBD)
Business
Regenicin, Inc. is a biotechnology firm dedicated to advancing and commercializing innovative technology for tissue-engineered skin substitutes. The company's primary offering, NovaDerm, is a multi-layered, living skin substitute engineered from a patient's own cells, designed to address severe burns and chronic wounds. This advanced solution aims to facilitate healing and regenerate healthy human skin. Additionally, Regenicin is developing TempaDerm, intended for smaller localized wound care, such as ulcers. These products are central to restoring the qualities of healthy skin, applicable across treatments for burns, persistent wounds, and various reconstructive surgical procedures. The company, initially incorporated in 2007, adopted the name Regenicin, Inc. in July 2010, succeeding its former identity as Windstar, Inc. Regenicin, Inc. is headquartered in Las Vegas, Nevada.